Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

Betts BC, St Angelo ET, Kennedy M, Young JW.

Blood. 2011 Nov 10;118(19):5340-3. doi: 10.1182/blood-2011-06-363390. Epub 2011 Sep 22.

2.

IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo.

Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM.

J Immunol. 2011 Jun 1;186(11):6329-37. doi: 10.4049/jimmunol.1100061. Epub 2011 Apr 27.

3.

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.

Arthritis Res Ther. 2011 Apr 21;13(2):R68. doi: 10.1186/ar3329.

4.

Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2.

Chen Y, Haines CJ, Gutcher I, Hochweller K, Blumenschein WM, McClanahan T, Hämmerling G, Li MO, Cua DJ, McGeachy MJ.

Immunity. 2011 Mar 25;34(3):409-21. doi: 10.1016/j.immuni.2011.02.011.

5.

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW.

Clin Cancer Res. 2011 Apr 1;17(7):1984-97. doi: 10.1158/1078-0432.CCR-10-3421. Epub 2011 Feb 25. Erratum in: Clin Cancer Res. 2011 Jun 1;17(11):3851. Wolchock, Jedd D [corrected to Wolchok, Jedd D].

6.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A.

J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.

7.

Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun Y, Lowler KP, Malter C, Nishimoto N, Hill GR, Reddy P.

Clin Cancer Res. 2011 Jan 1;17(1):77-88. doi: 10.1158/1078-0432.CCR-10-1198. Epub 2010 Nov 3.

8.

Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.

Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR.

Blood. 2010 Jun 24;115(25):5249-58. doi: 10.1182/blood-2009-11-255422. Epub 2010 Apr 9.

9.

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K.

J Immunol. 2010 May 1;184(9):5298-307. doi: 10.4049/jimmunol.0902819. Epub 2010 Apr 2.

10.

Th17 and regulatory T cells in mediating and restraining inflammation.

Littman DR, Rudensky AY.

Cell. 2010 Mar 19;140(6):845-58. doi: 10.1016/j.cell.2010.02.021. Review.

11.

Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.

Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, Brewin J, Openshaw P, Gaspar HB, Veys P, Amrolia PJ.

Blood. 2010 Jan 14;115(2):396-407. doi: 10.1182/blood-2009-08-235895. Epub 2009 Nov 4.

12.

Infliximab for managing steroid-refractory acute graft-versus-host disease.

Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1116-21. doi: 10.1016/j.bbmt.2009.05.019.

13.

Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H, Young J, Todorov I, Umetsu DT, Chen L, Iwakura Y, Kandeel F, Forman S, Zeng D.

Blood. 2009 Oct 1;114(14):3101-12. doi: 10.1182/blood-2009-05-219402. Epub 2009 Jul 14.

14.

Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR.

Blood. 2009 Jul 23;114(4):891-900. doi: 10.1182/blood-2009-01-197178. Epub 2009 Jun 2.

15.

Janus kinases in immune cell signaling.

Ghoreschi K, Laurence A, O'Shea JJ.

Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Review.

16.

The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells.

Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA.

J Leukoc Biol. 2008 Oct;84(4):973-80. doi: 10.1189/jlb.1107778. Epub 2008 Jul 23.

17.

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH.

Cancer Cell. 2008 Apr;13(4):321-30. doi: 10.1016/j.ccr.2008.02.017.

18.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG.

Cancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009.

19.

TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR.

Nature. 2008 May 8;453(7192):236-40. doi: 10.1038/nature06878. Epub 2008 Mar 26.

20.

The IL23 axis plays a key role in the pathogenesis of IBD.

McGovern D, Powrie F.

Gut. 2007 Oct;56(10):1333-6.

Supplemental Content

Support Center